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bstract
Herein is reported, for the first time, a simple and reliable chiral reversed-phase liquid chromatographic method coupled to ultraviolet (UV)
etection for simultaneous determination of eslicarbazepine acetate (ESL) and its metabolites, S-licarbazepine (S-LC), R-licarbazepine (R-LC)
nd oxcarbazepine (OXC), in mouse plasma and brain, liver and kidney tissue homogenates. All analytes and the internal standard were extracted
rom plasma and tissue homogenates by a solid-phase extraction procedure using Waters Oasis® hydrophilic–lipophilic balance cartridges. The
hromatographic separation was performed by isocratic elution with water/methanol (88:12, v/v), pumped at a flow rate of 0.7 mL min−1, on a Lichro-
ART 250-4 ChiraDex (-cyclodextrin, 5m) column at 30 ◦C. The UV detector was set at 225 nm. Calibration curves were linear (r2 ≥ 0.996)
n the ranges 0.4–8g mL−1, 0.1–1.5g mL−1 and 0.1–2g mL−1 for ESL and OXC and in the ranges 0.4–80g mL−1, 0.1–15g mL−1 and
.1–20g mL−1 for R-LC and S-LC in plasma, brain and liver/kidney homogenates, respectively. The overall precision not exceeded 11.6%
%CV) and the accuracy ranged from −3.79 to 3.84% (%bias), considering all analytes in all matrices. Hence, this method will be a useful tool to
haracterize the pharmacokinetic disposition of ESL in mice.
2007 Elsevier B.V. All rights reserved.
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o. Introduction
Eslicarbazepine acetate (ESL) [S-(−)-10-acetoxy-10,11-
ihydro-5H-dibenz/b,f/azepine-5-carboxamide], previously
nown as BIA 2-093, is a novel central nervous system
CNS)-active drug presently completing phase III clinical
rials, as add-on therapy in refractory partial epilepsy, and
ndergoing phase II clinical trials, as monotherapy in partial
pilepsy and in bipolar disorder [1]. Chemically, it shares with
xcarbazepine (OXC) the dibenzazepine nucleus bearing the
-carboxamide substituent, but is structurally different at the
∗ Corresponding author. Tel.: +351 239 855089; fax: +351 239 855099.
E-mail address: acfalcao@ff.uc.pt (A. Falca˜o).
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oi:10.1016/j.aca.2007.05.0560,11-position (Fig. 1) [2]. These molecular variations result
n differences in their metabolism and, consequently, in their
harmacological properties. Briefly, OXC is an achiral prodrug
hich, in humans, is stereoselectivelly reduced in liver to the
harmacologically active licarbazepine metabolite, appearing
n plasma as S-licarbazepine (S-LC) and R-licarbazepine
R-LC) in approximately a 4:1 enantiomeric ratio [3,4]. On the
ther hand, the chiral prodrug ESL is quickly and extensively
etabolized to S-LC (95–98%) and, in a minor extent, to R-LC
nd OXC [5,6]. Unlike OXC, ESL appears to present a more
avourable metabolic pathway, with a higher S/R licarbazepine
nantiomeric ratio, without losing anticonvulsant potency [6,7].
To our knowledge, up to date, in spite of OXC to be used
n the clinical practice for several years and ESL to be in final
hase of clinical trials, few studies have investigated the systemic
himic
d
m
S
t
I
u
t
t
c
o
m
b
a
r
m
f
t
t
d
t
m
p
L
m
m
2
2
1
p
O
n
(
M
h
p
a
K
2
(
a
p
d
l
t
d
w
F
b
w
a
l
h
(
f
F
sG. Alves et al. / Analytica C
isposition of their licarbazepine enantiomers [6,8–11]. Further-
ore, the differential pharmacokinetic disposition of R-LC and
-LC in brain, liver and kidney tissues remains unknown, con-
ributing for that perhaps the lack of an economical chiral assay.
n fact, only three chiral liquid chromatographic methods with
ltraviolet detection (LC-UV) are reported in the literature for
he quantification of licarbazepine enantiomers [8,12,13], and
hey were all developed under normal phase chromatographic
olumns with expensive mobile phases essentially composed
f n-hexane. In addition, another chiral liquid chromatographic
ethod with mass spectrometry detection (LC–MS) has also
een referred to determine ESL and its metabolites S-LC, R-LC
nd OXC, but it was not yet completely described [6,14].
Actually, the clinical development of a new drug always
uns together with non-clinical studies, since for ethical aspects
any experiments could not be performed in humans. There-
ore, the availability of an accurate and easy-to-use LC method
o quantify ESL and its metabolites in an appropriate experimen-
al model will be important to complete the pharmacokinetic
ata that are arising from clinical trials. Thus, bearing in mind
he metabolism specie-dependent of ESL and being mouse the
ost relevant specie to humans in this case [5,6,14], the pur-
ose of this paper is to describe the first chiral reversed-phase
C-UV method developed and validated to simultaneous deter-
ination of ESL and its metabolites S-LC, R-LC and OXC in
ouse plasma and brain, liver and kidney tissue homogenates.
. Experimental.1. Chemicals
Standards of ESL (BIA 2-093, lot number 0000012976,
00% pure), S-LC (BIA 2-194, lot number PC020131B, 99.79%
−
w
d
ig. 1. Chemical structures of eslicarbazepine acetate (ESL), S-licarbazepine (S-LC),
tandard (I.S.).a Acta 596 (2007) 132–140 133
ure), R-LC (BIA 2-195, lot number PC040414, 100% pure),
XC (lot number 97.12.17, >98% pure) and BIA 2-265 (lot
umber PC050704, 97.4% pure) used as internal standard
I.S.), were kindly supplied by BIAL (Porto, Portugal) (Fig. 1).
ethanol (LC grade, SDS), water milli-Q (LC grade, >15 M,
ome-made), acetonitrile, ethyl acetate, sodium dihydrogen
hosphate dihydrate, di-sodium hydrogen phosphate dehydrate
nd hydrochloric acid fuming 37% were purchased from Merck
GaA (Darmstadt, Germany).
.2. Animal experiments
Adult male CD-1 mice obtained from Harlan-Interfauna
Barcelona, Spain), weighing 30–35 g, were housed in local
nimal facilities with light (12 h light/dark cycle) and tem-
erature (22 ± 1 ◦C) controlled environment. A regular chow
iet (4RF21, Mucedola, Italy) and tap water were available ad
ibitum until the experimental procedures. Mice not subjected
o any pharmacological treatment were used as a source of
rug-free mouse plasma and brain, liver and kidney tissues,
hich were used as blank matrices in the validation studies.
or that, blood samples were collected into heparinised tubes
y decapitation preceded of cervical dislocation. The plasma
as separated by centrifugation at 4000 rpm for 10 min (4 ◦C)
nd stored at −30 ◦C until use. After exsanguination, brain,
iver and kidneys were quickly removed, weighed and then
omogenised (4 mL g−1) in a 0.1 M sodium phosphate buffer
pH 5). The tissue homogenates were centrifuged at 4800 rpm
or 15 min (4 ◦C) and the supernatants were also stored at
30 ◦C.
All animal experimentation was conducted in accordance
ith the European Directive (86/609/EEC) for the accommo-
ation and care of laboratory animals and the experimental
R-licarbazepine (R-LC), oxcarbazepine (OXC) and BIA 2-265 used as internal
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rocedures were approved by the Portuguese Veterinary General
ivision.
.3. Apparatus and chromatographic conditions
LC analysis was performed on a BAS-480 Liquid Chro-
atograph equipped with a PM-80 pump, a Rheodyne manual
njector with a 20L loop, a BAS UV-116 UV-Vis detector,
BAS LC-22C Temperature Controller, a BAS DA-5 Chro-
atography Control and a Data System Interface (all from
ioanalytical Systems, West Lafayette, IN, USA). Data col-
ection and integration were achieved by means of a BAS
hromgraph Control and Chromgraph Report software version
.30.
Chromatographic separation of all four drugs and I.S. was
arried out at 30 ◦C by isocratic elution with water/methanol
88:12, v/v), at a flow rate of 0.7 mL min−1, on a LiChroCART
50-4 ChiraDex (-cyclodextrin, 5m) column protected by a
iChroCART 4-4 ChiraDex (-cyclodextrin, 5m) guard col-
mn purchased from Merck KGaA (Darmstadt, Germany). The
obile phase was filtered through a 0.45m filter and degassed
ltrasonically for 15 min before use. The injection volume was
0L and the analytes were detected at 225 nm.
.4. Stock solutions, calibration standards and quality
ontrol samples
The stock solutions of ESL (2 mg mL−1), S-LC
10 mg mL−1), R-LC (10 mg mL−1), OXC (2 mg mL−1)
nd I.S. (1 mg mL−1) were prepared by dissolving appropriate
mounts of each compound in acetonitrile. These solutions
ere adequately diluted with acetonitrile in order to give S-LC
nd R-LC 2 mg mL−1 solutions and ESL, S-LC, R-LC and
XC 200g mL−1 solutions. The prepared solutions were used
ppropriately to afford six combined spiking solutions of all
our drugs with final concentrations of 10, 50, 500, 1000, 1500
nd 2000g mL−1 for S-LC and R-LC, and 10, 20, 50, 100, 150
nd 200g mL−1 for ESL and OXC. An I.S. working solution
f 200g mL−1 was prepared by diluting appropriately the
espective stock solution. All solutions were stored at 4 ◦C and
rotected from light for one month, except the I.S. working
olution, which was prepared on each day of analysis.
Blank plasma and supernatants of the different tissue
omogenates were spiked with the appropriate combined solu-
ions to obtain five calibration standards containing ESL and
XC in the ranges of 0.4–8g mL−1, 0.1–1.5g mL−1 and
.1–2g mL−1 for plasma, brain and liver/kidney, respectively,
nd containing each licarbazepine enantiomer in the ranges of
.4–80g mL−1, 0.1–15g mL−1 and 0.1–20g mL−1 for the
espective matrices previously referred. Quality control (QC)
amples were prepared independently in the same biological
atrices..5. Sample preparation and extraction procedure
Aliquots of mouse plasma (250L) were added to 750L
f 0.1 M sodium phosphate buffer (pH 5) spiked with 10L
q
c
s
(a Acta 596 (2007) 132–140
f the I.S. working solution. The samples were vortex-
ixed and loaded into Waters (Milford, MA, USA) Oasis®
ydrophilic–lipophilic balance (HLB) extraction cartridges
30 mg, 1 mL), which were previously conditioned with 1 mL
f methanol, 1 mL of acetonitrile and 1 mL of water/acetonitrile
95:5, v/v). After sample elution, the loaded cartridges were
ubmitted to −30 kPa and washed twice with 1 mL of water and
wice with 1 mL of water/acetonitrile (95:5, v/v). After drying
he sorbent under airflow for 5 min, the analytes were eluted
ith 1 mL of ethyl acetate under gentle vacuum and then the
artridges were dried for 30 s at −30 kPa. The eluates were
vaporated to dryness under a nitrogen stream at 45 ◦C and
he residues reconstituted in 100L of LC mobile phase, vor-
exed for approximately 30 s and placed in an ultrasonic bath
t room temperature for approximately 1 min. Following this,
he reconstituted extracts were transferred to 0.22m Spin-
centrifugal filters, centrifuged at 13,400 rpm for 2 min and
0L of the final filtered samples were injected onto the LC
ystem.
The supernatant samples of tissue (brain, liver and kidney)
omogenates were thawed, centrifuged (13,400 rpm for 20 min)
second time to give clear supernatants and 1 mL was used for
nalysis after spiking with 10L of the I.S. working solution.
fterwards, the analytes of supernatant samples were extracted
y a solid-phase extraction (SPE) procedure as described for
lasma samples, but with some differences in the washing steps
nd vacuum conditions (−40 kPa). As brain, liver and kidney
atrices are more complexes than plasma, the loaded cartridges
ere washed with 1 mL of water and 1 mL of water/acetonitrile
95:5, v/v) for three or four times, in brain samples or in liver
nd kidney samples, respectively. The corresponding eluates
ere processed in the same way as those obtained from plasma
amples.
.6. Method validation
The method was validated according to the general rec-
mmendations published in the last few years with regard to
ioanalytical method validation and acceptance criteria for val-
dation parameters: selectivity, linearity, sensitivity, precision,
ccuracy, sample dilution, recovery and stability [15,16].
Selectivity was studied investigating the absence of endoge-
ous interferences from extracts of blank samples (plasma and
upernatant of brain, liver and kidney homogenates) of six dif-
erent mice.
To evaluate the linearity of the analytical method, calibra-
ion curves were prepared using five calibration standards and
ssayed on 5 separate days (n = 5). The calibration curves were
onstructed by plotting drug/I.S. peak height ratio as a func-
ion of the respective concentrations. The data were subjected
o a weighted linear regression analysis using 1/x2 as weight-
ng factor, which was chosen taking the plots and the sums of
bsolute percentage relative error into account [17]. The limit of
uantification (LOQ), defined as the lowest concentration of the
alibration curve that can be measured with acceptable preci-
ion and accuracy, was established using five extracted samples
n = 5). The limit of detection (LOD), defined as the lowest con-
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entration that can be distinguished from the noise level, was
etermined after successive dilutions of the lowest calibration
tandard and it was established by instrumental evaluation taking
nto account a signal-to-noise ratio of three.
Intra and interday precision and accuracy were assessed by
C samples, using replicates (n = 5) at three concentration lev-
ls (low, medium and high) representative of the calibration
ange. The acceptance criterion for intra and interday precision
expressed as percentage of coefficient of variation, %CV) was
CV no more than 15% (or 20% in the LOQ) and for intra andnterday accuracy (expressed as percentage of deviation from
ominal value, % bias) was a bias within ±15% (or ±20% in
he LOQ).
(
t
ig. 2. Typical LC-UV chromatograms of extracted mouse samples. (a1) Blank and (a
SL (0.8g mL−1); (b1) blank and (b2) spiked supernatant of brain homogenate with I
c1) blank and (c2) spiked supernatant of liver homogenate with I.S. (2g mL−1), R
d2) spiked supernatant of kidney homogenate with I.S. (2g mL−1), R-LC and S-LCa Acta 596 (2007) 132–140 135
The dilution effect (1:10) was investigated in plasma and
n supernatant of liver and kidney tissue homogenates with
ppropriate QC samples (40g mL−1 for ESL and OXC
nd 400g mL−1 for licarbazepine enantiomers in plasma;
0g mL−1 for ESL and OXC and 100g mL−1 for licar-
azepine enantiomers in liver and kidney) to ensure that samples
xceeding the highest concentration of the calibration range
ould be appropriately diluted with the respective blank matrix
nd accurately quantified. The precision and accuracy of diluted
amples were determined in both intra and interday assays
n = 5).
Drug relative recoveries were calculated at three concen-
ration levels by comparing the drug/I.S. peak height ratios of
2) spiked plasma with I.S. (8g mL−1), R-LC and S-LC (2g mL−1), OXC and
.S. (2g mL−1), R-LC and S-LC (0.5g mL−1), OXC and ESL (0.2g mL−1);
-LC and S-LC (0.5g mL−1), OXC and ESL (0.2g mL−1); (d1) blank and
(0.5g mL−1), OXC and ESL (0.2g mL−1).
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xtracted samples with the corresponding ratios obtained with
on-extracted standards (n = 5). The I.S. absolute recovery was
lso determined by calculating the I.S. peak height ratio of
xtracted samples and non-extracted standards (n = 5).
The stability of ESL and its metabolites was assessed in
ll matrices, at two concentration levels (0.8g mL−1 and
g mL−1 for ESL and OXC and 2g mL−1 and 40g mL−1
or licarbazepine enantiomers in plasma; 0.2g mL−1 and
g mL−1 for ESL and OXC and 0.5g mL−1 and 10g mL−1
or licarbazepine enantiomers in brain, liver and kidney sam-
les), by 24 h at 4 ◦C and 30 days at −30 ◦C to simulate sample
andling and storage time in the freezer before analysis (n = 5).
tability was assessed comparing the QC samples analysed
efore (reference samples) and after being exposed to the con-
itions for stability assessment (stability samples), considering
s acceptable stability criterion the stability sample/reference
ample ratio of 85–115%.
. Results and discussion
.1. Method development and selectivity
Since cyclodextrins have been widely used as chiral selec-
ors [18] and a LiChroCART 250-4 ChiraDex (-cyclodextrin,
m) column has been used to separate ESL metabolites (S-
C, R-LC and OXC) by LC–MS using water/methanol (80:20,
/v) at a flow rate of 0.8 mL min−1 [6,14], these chromato-
raphic conditions coupled to UV detection at 210 nm [8]
ere predefined for the first experiments. However, under these
onditions, the resolution between R-LC and S-LC was not
nough. Thus, after extensive experiments with standard solu-
t
o
c
m
able 1
alibration curve parametersa for ESL, S-LC, R-LC and OXC in mouse plasma and s
atrix/drug Calibration standards (g mL−1) Slope
lasma
ESL 0.4, 0.8, 2, 4, 8 0.0578
S-LC 0.4, 2, 20, 40, 80 0.1201
R-LC 0.4, 2, 20, 40, 80 0.1425
OXC 0.4, 0.8, 2, 4, 8 0.1786
rain
ESL 0.1, 0.2, 0.5, 1, 1.5 0.2295
S-LC 0.1, 0.5, 5, 10, 15 0.4127
R-LC 0.1, 0.5, 5, 10, 15 0.5178
OXC 0.1, 0.2, 0.5, 1, 1.5 0.6460
iver
ESL 0.1, 0.2, 0.5, 1, 2 0.2199
S-LC 0.1, 0.5, 5, 10, 20 0.4186
R-LC 0.1, 0.5, 5, 10, 20 0.5236
OXC 0.1, 0.2, 0.5, 1, 2 0.6726
idney
ESL 0.1, 0.2, 0.5, 1, 2 0.2025
S-LC 0.1, 0.5, 5, 10, 20 0.4084
R-LC 0.1, 0.5, 5, 10, 20 0.4952
OXC 0.1, 0.2, 0.5, 1, 2 0.6026
a Equation of the calibration curve y = bx + a, where x is the drug concentration, e
rbitrary height units.a Acta 596 (2007) 132–140
ions, the chromatographic separation of the target analytes was
ttained with a mixture of water/methanol (88:12, v/v), at a flow
ate of 0.7 mL min−1, on a LiChroCART 250-4 ChiraDex (-
yclodextrin, 5m) column protected by a LiChroCART 4-4
hiraDex (-cyclodextrin, 5m) guard column, at 30 ◦C. Then,
he flowing step was the selection of an adequate I.S., chemi-
ally related to the analytes of interest. As starting point was
ssayed the 10,11-dihydrocarbamazepine already used as I.S.
6,14]. However, this compound was shown to be inadequate
ecause the chromatographic run time would increase signifi-
antly. Therefore, several compounds with chemical structures
imilar to those of the analytes, provided by BIAL Laboratories,
ere tested for potential use as I.S. Among them, BIA 2-265
as selected by its appropriate retention time and sharpened
ymmetric peak, taking into account at the same time that it is
ot a metabolite of ESL.
Given that, qualitatively, ESL and OXC have a similar
etabolism, the SPE procedure here developed to extract ESL
nd its metabolites from mouse samples was based on the meth-
ds presented by Hainzl et al. [14] and Mandrioli et al. [19]. The
ptimization of the extraction procedure was achieved in Waters
Milford, MA, USA) Oasis® HLB cartridges (30 mg, 1 mL) with
he experimental conditions mentioned in Section 2.5.
The chiral separation of licarbazepine enantiomers, OXC,
SL and I.S. in mouse plasma and tissue (brain, liver and kidney)
omogenates was achieved successfully using the chromato-
raphic conditions and the SPE procedure developed. Under
hese conditions, the last-eluting compound was ESL and the
rder of elution was I.S., R-LC, S-LC, OXC and ESL. Typical
hromatograms of extracts from blank and spiked samples of
ouse plasma and tissue homogenates are shown in Fig. 2. The
upernatant of brain, liver and kidney homogenates (n = 5)
(b) Intercept (a) Determination coefficient (r2)
0.0000 0.996
−0.0004 0.998
−0.0062 0.998
0.0069 0.996
−0.0004 0.998
0.0016 0.999
0.0029 0.999
−0.0071 0.998
−0.0008 0.998
0.0009 0.999
−0.0030 0.999
−0.0052 0.998
−0.0004 0.999
−0.0013 0.999
−0.0018 0.999
−0.0056 0.997
xpressed in g mL−1, and y is the drug to I.S. peak height ratio, expressed in
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hromatograms demonstrate that in all drug-free matrices no
ndogenous compounds are interfering at the retention times of
he I.S. or the analytes.
.2. Calibration curve
The calibration curves were linear for ESL and OXC
ver the concentration ranges 0.4–8g mL−1 in mouse
lasma, 0.1–1.5g mL−1 in supernatant of brain homogenate
nd 0.1–2g mL−1 in supernatants of liver and kid-
ey homogenates, and for each licarbazepine enantiomer
0
o
w
0
able 2
ntra- and interday precision (% CV) and accuracy (% bias) for the simultaneous dete
rain, liver and kidney homogenates (n = 5)
Nominal
a Assay
Intraday
% CV % Bias % CV % Bia
lasma ESL OXC
0.4 6.06 −3.53 4.66 −2.49
4 2.05 −0.300 2.13 0.340
8 1.99 −2.32 2.37 −1.73
S-LC R-LC
0.4 3.52 −0.840 3.14 −0.810
0 2.73 0.250 2.70 0.730
0 1.78 −2.77 1.67 −2.50
rain ESL OXC
0.1 7.63 0.100 4.21 1.62
1 3.84 −2.06 2.82 −0.990
1.5 5.62 1.50 5.10 2.72
S-LC R-LC
0.1 4.93 0.200 4.31 −0.010
0 3.89 0.560 3.94 0.360
5 5.72 −0.130 5.77 −0.140
iver ESL OXC
0.1 3.76 −1.37 4.69 0.500
1 1.61 −3.79 2.94 −1.57
2 3.49 0.0100 4.01 0.160
S-LC R-LC
0.1 4.20 −0.0100 5.73 −0.240
0 1.80 0.570 1.88 0.460
0 1.87 −0.960 1.88 −0.930
idney ESL OXC
0.1 7.71 1.94 9.70 3.84
1 1.75 3.35 3.27 3.30
2 2.85 −0.170 4.16 1.04
S-LC R-LC
0.1 7.01 0.350 4.13 0.440
0 3.18 1.62 3.14 1.85
0 4.01 1.07 4.07 0.420
a Nominal concentration (g mL−1).a Acta 596 (2007) 132–140 137
n the ranges of 0.4–80g mL−1, 0.1–15g mL−1 and
.1–20g mL−1 in plasma, brain and liver/kidney, respectively.
he calibration curves were subjected to weighted linear regres-
ion analysis and the respective parameters are shown in Table 1,
here the determination coefficients demonstrate good linearity
or all analytes in all studied matrices (r2 ≥ 0.996). The lowest
alibration standard corresponded to the LOQ (0.4g mL−1 or
.1g mL−1 using 250L of plasma or 1 mL of supernatant
f tissue homogenates, respectively), which could be measured
ith acceptable precision and accuracy (≤20%). The LOD was
.1g mL−1 for ESL and 0.04g mL−1 for OXC, S-LC and R-
rmination of ESL, S-LC, R-LC and OXC in mouse plasma and supernatant of
Interday
s % CV % Bias % CV % Bias
ESL OXC
3.21 −2.59 4.17 −2.57
2.60 0.0400 3.15 0.180
3.49 −0.880 3.69 −1.34
S-LC R-LC
5.32 −1.31 3.76 −0.980
3.40 −1.26 3.55 −0.350
4.94 −2.60 5.03 −1.85
ESL OXC
11.6 −1.81 5.15 1.53
5.94 −3.00 6.38 −1.29
5.81 0.370 6.94 2.27
S-LC R-LC
0 9.62 −0.0200 9.79 −0.200
4.97 0.510 4.83 0.340
4.57 0.0900 4.50 0.150
ESL OXC
5.93 0.950 4.67 1.44
2.12 0.650 3.73 1.01
2.70 −0.590 1.01 0.760
S-LC R-LC
4.76 −0.110 5.96 −0.210
3.20 1.15 3.09 1.29
3.49 0.0500 3.45 0.150
ESL OXC
8.89 0.990 7.17 2.82
3.32 1.21 5.65 0.690
2.95 −0.0300 2.95 1.79
S-LC R-LC
10.4 0.390 10.1 0.310
3.46 1.26 3.44 1.13
2.58 −0.220 2.54 −1.04
1 himica Acta 596 (2007) 132–140
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Table 3
Relative recoveries (%) of ESL, S-LC, R-LC and OXC in mouse plasma and
supernatant of brain, liver and kidney homogenates
CNominala nb Relative recovery (%)
Mean % CV Mean % CV
Plasma ESL OXC
0.4 5 95.1 3.57 92.1 5.43
4 5 98.0 2.30 96.7 2.06
8 5 95.1 2.86 91.0 3.37
15 96.1 3.26 93.3 4.64
S-LC R-LC
0.4 5 103 4.27 100 2.84
40 5 105 2.13 106 2.30
80 5 98.2 2.69 96.5 3.01
15 102 4.23 101 4.79
Brain ESL OXC
0.1 5 90.3 7.05 87.8 3.60
1 5 95.2 5.90 87.4 6.60
1.5 5 97.1 2.30 92.7 2.39
15 94.2 6.18 89.3 5.22
S-LC R-LC
0.1 5 95.7 3.32 98.8 6.10
10 5 94.7 5.77 95.7 5.80
15 5 98.6 3.13 99.3 2.91
15 96.3 4.54 97.9 5.37
Liver ESL OXC
0.1 5 97.7 8.40 97.5 4.23
1 5 96.1 2.53 88.7 3.79
2 5 99.2 4.74 97.6 4.87
15 97.7 5.92 94.6 6.18
S-LC R-LC
0.1 5 97.4 6.85 95.5 5.21
10 5 97.1 3.49 97.9 3.39
20 5 97.6 3.54 98.1 3.46
15 97.4 4.89 97.2 4.27
Kidney ESL OXC
0.1 5 93.2 4.53 90.4 3.48
1 5 93.9 3.16 88.0 2.66
2 5 91.6 3.30 88.9 2.19
15 92.9 3.85 89.1 3.04
S-LC R-LC
0.1 5 98.3 2.18 93.3 2.89
10 5 92.6 3.42 93.1 3.45
20 5 96.0 2.01 96.3 1.98
15 95.6 3.56 94.2 3.21
E
a38 G. Alves et al. / Analytica C
C in plasma, and 0.025g mL−1 for ESL and 0.01g mL−1
or its metabolites in supernatant of mouse tissue homogenates.
.3. Precision and accuracy
The data presented in Table 2 show the intra and interday
recision and accuracy for plasma and supernatant of tissue
omogenates. The overall intra and interday precision (%CV)
s within 11.6% and the accuracy (%bias) varied from −3.79
o 3.84%. These data demonstrate that both precision and accu-
acy are within the acceptable limits in all matrices, being the
ethod precise and accurate to determine these drugs from
ouse plasma, brain, liver and kidney samples.
The sample dilution (1:10) was also investigated intra and
nterday in plasma, liver and kidney samples and showed to
e precise (CV < 5.0%) and accurate (bias ranged from −2.94
o −1.35%) in the studied biological matrices. These results
evealed that a 10-fold dilution with blank matrix can be rightly
pplied if the concentration of a trial sample exceeds the highest
oncentration of the calibration curve.
.4. Recovery
The relative drug recoveries from plasma and tissue
omogenates were estimated and presented in Table 3. The
ean relative recoveries, taking the ESL and its metabolites into
ccount in all matrices, ranged from 89.1 to 102%. As shown in
able 3, the values of CV were relatively low, which suggests
onsistent average recoveries over the evaluated concentration
ange. The absolute recovery of the I.S. in mouse plasma and
issue homogenates was also evaluated, with values between
3.5% and 89.1% and CV within 5.77%.
.5. Stability
From drug stability data obtained in plasma and mouse tis-
ue homogenates for ESL and its metabolites no significant
oss was observed when spiked samples were stored for 30
ays at −30 ◦C, but ESL showed instability in plasma and
idney samples when stored at 4 ◦C for 24 h. However, that
mportant loss detected for ESL at 4 ◦C for 24 h in plasma
nd kidney samples is not worrying, since after dissection
he mouse samples remain on ice no more than few minutes
ntil storage at −30 ◦C. On the other hand, the preclinical
nd clinical studies have demonstrated that the prodrug ESL is
apidly metabolised and appears below the limit of quantifica-
ion (BLQ) at all time points post-dose at all studied dose levels
5–7,14].
.6. Method application
The application of the proposed LC-UV assay to real samples
as also demonstrated following a single oral administration of
SL 500 mg kg−1. The samples of interest (plasma, brain, liver
nd kidneys) were taken at 0.5 h post-dose and immediately pro-
essed as indicated in Sections 2.2 and 2.5. As indicated in Fig. 3,
d
e
a
[a Nominal concentration (g mL−1).
b n, number of samples.
SL metabolites were successful separated in mouse plasma
nd supernatant of brain, liver and kidney tissue homogenates,
espite the low and high concentrations of R-LC and S-LC gen-
rated in vivo. However, R-LC only appeared in measurable
mounts in liver (Fig. 3c) and, in agreement with previous studies
14], the parent compound was not detected.
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Fig. 3. Chromatograms obtained from mouse samples at 0.5 h after oral administration of ESL 500 mg kg−1. The peaks correspond to the following concentrations:
(a) R-LC (BLQ), S-LC (31.0g mL−1) and OXC (3.26g mL−1) in plasma; (b) R-LC (BLQ), S-LC (1.91g mL−1) and OXC (0.88g mL−1) in brain supernatant;
(c) R-LC (0.16g mL−1), S-LC (9.61g mL−1) and OXC (0.48g mL−1) in liver supernatant; (d) R-LC (BLQ), S-LC (8.73g mL−1) and OXC (0.57g mL−1) in
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Ridney supernatant.
. Conclusion
Up to date, none LC-UV method was published to quan-
ify ESL and its metabolites, only an LC–MS assay is available
6,14]. Thus, this paper describes the first chiral reversed-phase
C-UV–SPE method fully validated to quantify ESL, R-LC, S-
C and OXC in mouse plasma and tissue homogenates. The
ethod seems to be precise and accurate and the SPE pro-
edure developed gives good results in terms of selectivity,
eproducibility and extraction yield. Compared to the literature
hiral methods for analysis of R-LC and S-LC [8,12,13], the
ssay presented here offers as major advantages the very sim-
le and economical chromatographic conditions with a mobile
hase essentially composed of water.
Our results clearly evidenced, by the corresponding retention
ime values, that S-LC forms more stable transient diastere-
meric complexes than R-LC with the ChiraDex stationary
hase, and thus, the S-LC elution occurs later than that for R-LC.
ence, taking into account the unique properties of cyclodex-
rins to generate hydrophobic cavities with hydrophilic exterior
aces in aqueous solutions, the chiral discrimination between R-
C and S-LC will be due to the differences in their steric fit in
he chiral cavities and their ability to establish hydrogen bonds.
owever, other intermolecular interactions may contribute for
he enantiomeric resolution [18,20].The method was validated in mouse tissue samples given that
he preclinical and clinical data already available for these com-
ounds indicate that, among the small laboratory animals, the
ouse model showed similar metabolic pathways to humans
5,6,14]. Consequently, plasma, brain, liver and kidney matri-
es were selected, since they represent the main body tissues
f interest to perform pharmacokinetic studies with CNS-active
rugs. In conclusion, this LC-UV method allows the reliable
nd simultaneous determination of ESL metabolites in mice,
upporting future non-clinical studies in order to clarify the
harmacokinetic data that are progressively arising from man.
cknowledgements
This work was supported by Fundac¸a˜o para a Cieˆncia e a Tec-
ologia, Programa POCTI (SFRH/BD/12694/2003), Portugal
nd by BIAL, Portugal.
eferences
[1] L. Almeida, P. Soares-da-Silva, Neurotherapeutics 4 (2007) 88.
[2] J. Benes, A. Parada, A.A. Figueiredo, P.C. Alves, A.P. Freitas, D.A. Lear-
month, R.A. Cunha, J. Garret, P. Soares-da-Silva, J. Med. Chem. 42 (1999)
2582.
[3] T.W. May, E. Korn-Merker, B. Rambeck, Clin. Pharmacokinet. 42 (2003)
1023.
1 himic
[
[
[
[
[
[
[
[40 G. Alves et al. / Analytica C
[4] G. Flesch, Clin. Drug Invest. 24 (2004) 185.
[5] L. Almeida, P. Soares-da-Silva, J. Clin. Pharmacol. 44 (2004) 906.
[6] L. Almeida, A. Falca˜o, J. Maia, D. Mazur, M. Gellert, P. Soares-da-Silva,
J. Clin. Pharmacol. 45 (2005) 1062.
[7] L. Almeida, P. Soares-da-Silva, Drugs R. D. 4 (2003) 269.
[8] G. Flesch, E. Francotte, F. Hell, P.H. Degen, J. Chromatogr. 581 (1992)
147.
[9] A. Volosov, A. Sintov, M. Bialer, Ther. Drug Monit. 21 (1999) 219.
10] A. Volosov, S. Xiaodong, E. Perucca, B. Yagen, A. Sintov, M. Bialer, Clin.
Pharmacol. Ther. 66 (1999) 547.
11] A. Volosov, B. Yagen, M. Bialer, Epilepsia 41 (2000) 1107.
12] S. Pichini, I. Altieri, A.R. Passa, P. Zuccaro, R. Pacifici, J. Liq. Chromatogr.
18 (1995) 1533.
[
[
[a Acta 596 (2007) 132–140
13] A. Volosov, M. Bialer, S. Xiaodong, E. Perucca, A. Sintov, B. Yagen, J.
Chromatogr. B 738 (2000) 419.
14] D. Hainzl, A. Parada, P. Soares-da-Silva, Epilepsy Res. 44 (2001) 197.
15] V.P. Shah, K.K. Midha, J.W.A. Findlay, H.M. Hill, J.D. Hulse, I.J.
McGilveray, G. Mckay, K.J. Miller, R.N. Patnaik, M.L. Powell, A. Tonelli,
C.T. Viswanathan, A. Yacobi, Pharm. Res. 17 (2000) 1551.
16] F.T. Peters, H.H. Maurer, Accred. Qual. Assur. 7 (2002) 441.
17] A.M. Almeida, M.M. Castel-Branco, A.C. Falca˜o, J. Chromatogr. B 774(2002) 215.
18] S.M. Han, Biomed. Chromatogr. 11 (1997) 259.
19] R. Mandrioli, N. Ghedini, F. Albani, E. Kenndler, M.A. Raggi, J. Chro-
matogr. B 783 (2003) 253.
20] X. Wang, C.B. Ching, Chirality 14 (2002) 798.
